oseltamivir ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antivirals neuraminidase inhibitors 2001 196618-13-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ebilfumin
  • oseltamivir
  • tamvir
  • tamiflu
  • oseltamivir phosphate
Oseltamivir phosphate is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. Oseltamivir carboxylate is an inhibitor of influenza virus neuraminidase affecting release of viral particles. The median IC50 values of oseltamivir against influenza A/H1N1, influenza A/H3N2, and influenza B clinical isolates were 2.5 nM (range 0.93-4.16 nM, N=74), 0.96 nM (range 0.13 - 7.95 nM, N=774), and 60 nM (20-285 nM, N=256), respectively, in a neuraminidase assay with a fluorescently labeled MUNANA substrate. Although oseltamivir was suggested as a potential treatment and included in various antiviral regimens used during the early stages of the COVID-19 pandemic, the drug does not appear to have in vitro activity against SARS-CoV-2 and there are no data to support the use of oseltamivir or other neuraminidase inhibitors in the treatment of COVID-19.
  • Molecular weight: 312.41
  • Formula: C16H28N2O4
  • CLOGP: 2.13
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 90.65
  • ALOGS: -2.66
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 99 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.71 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 75 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 1.60 mg/mL Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma) 0.74 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.545 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 7.362 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 8.831 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 4.808 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 69.220 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 64.960 % High 1
herg hERG pIC50 4.421 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 11.830 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 22.387 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 67.480 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 49
kinase-selectivity-class AXL,CAMK2D,EIF2AK3,GRK2,MAP2K6,PDK1,TEK 7
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 3.436 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 9.268 High 1
mh-clint Mouse hepatocyte intrinsic clearance 24.831 High 1
mppb Mouse plasma protein binding (% unbound) 67.020 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 13.152 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 70.820 % High 1
rat-kpuu-brain Rat brain Kpuu 0.061 % High 1
rh-clint Rat hepatocyte intrinsic clearance 13.032 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 89.950 % High 1
rppb Rat plasma protein binding (% unbound) 63.790 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 891.251 uM High 1

Approvals:

DateAgencyCompanyOrphan
Oct. 27, 1999 FDA ROCHE
June 20, 2002 EMA Roche Registration GmbH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
No adverse event 1517.21 16.41 614 25958 67368 90534507
Abnormal behaviour 596.67 16.41 231 26341 22397 90579478
Exposure during pregnancy 527.65 16.41 485 26087 237925 90363950
Pregnancy 469.60 16.41 267 26305 61780 90540095
Chest X-ray abnormal 373.53 16.41 112 26460 4970 90596905
Pulmonary function test abnormal 369.00 16.41 97 26475 2642 90599233
Ear pruritus 325.31 16.41 108 26464 6695 90595180
Blood lactic acid increased 309.62 16.41 111 26461 8667 90593208
Off label use 281.94 16.41 831 25741 1101421 89500454
Swollen tongue 277.43 16.41 171 26401 45785 90556090
Influenza 250.14 16.41 253 26319 139011 90462864
Nasal polyps 247.88 16.41 100 26472 10780 90591095
Drug ineffective for unapproved indication 246.42 16.41 183 26389 66461 90535414
Breath sounds abnormal 246.05 16.41 110 26462 15276 90586599
Angioedema 239.55 16.41 178 26394 64698 90537177
Rhinitis allergic 224.52 16.41 106 26466 16679 90585196
Swelling face 222.43 16.41 187 26385 81165 90520710
Dysphonia 221.59 16.41 168 26404 62916 90538959
Upper-airway cough syndrome 216.12 16.41 100 26472 15035 90586840
Hallucination 210.62 16.41 166 26406 65793 90536082
Platelet count increased 208.41 16.41 108 26464 20751 90581124
Vasculitis 205.44 16.41 110 26462 22583 90579292
Sneezing 203.10 16.41 120 26452 29749 90572126
Full blood count abnormal 180.69 16.41 120 26452 36477 90565398
Lacrimation increased 171.72 16.41 104 26468 26958 90574917
Eye pruritus 170.04 16.41 106 26466 28921 90572954
Eosinophilia 166.64 16.41 104 26468 28429 90573446
Blood potassium decreased 145.65 16.41 117 26455 47610 90554265
Premature delivery 144.46 16.41 107 26465 38655 90563220
Enterocolitis haemorrhagic 135.20 16.41 40 26532 1692 90600183
Rhinorrhoea 124.10 16.41 141 26431 88175 90513700
Acute respiratory distress syndrome 115.53 16.41 83 26489 28603 90573272
Pathogen resistance 107.74 16.41 51 26521 8064 90593811
Nasal congestion 90.76 16.41 117 26455 83297 90518578
Systemic lupus erythematosus 89.19 16.41 4 26568 361892 90239983
Alopecia 87.82 16.41 19 26553 495052 90106823
Synovitis 80.10 16.41 4 26568 329748 90272127
Normal newborn 79.29 16.41 61 26511 23301 90578574
Chest discomfort 74.17 16.41 140 26432 138225 90463650
Respiratory failure 73.89 16.41 128 26444 118290 90483585
Fatigue 67.84 16.41 149 26423 1153874 89448001
Therapeutic product effect decreased 65.44 16.41 4 26568 277567 90324308
Treatment failure 64.43 16.41 7 26565 303921 90297954
Infusion related reaction 64.41 16.41 21 26551 416759 90185116
Seizure 62.32 16.41 138 26434 152491 90449384
H1N1 influenza 61.88 16.41 23 26549 1987 90599888
Influenza virus test positive 60.33 16.41 13 26559 145 90601730
Joint swelling 59.61 16.41 37 26535 503263 90098612
Pain 56.56 16.41 131 26441 996210 89605665
Maternal exposure during pregnancy 55.75 16.41 231 26341 359832 90242043
Respiratory syncytial virus infection 55.69 16.41 36 26536 10444 90591431
Mobility decreased 55.16 16.41 5 26567 250729 90351146
Swelling 55.13 16.41 27 26545 419031 90182844
Impaired healing 53.37 16.41 4 26568 234195 90367680
Pericarditis 52.96 16.41 8 26564 270143 90331732
Pneumonia influenzal 52.43 16.41 21 26551 2219 90599656
Vomiting 51.07 16.41 400 26172 787893 89813982
Asthma 50.49 16.41 171 26401 241989 90359886
Weight increased 50.48 16.41 30 26542 417897 90183978
Analgesic therapy 50.19 16.41 15 26557 657 90601218
Glossodynia 50.07 16.41 16 26556 321763 90280112
Cough 49.69 16.41 227 26345 368735 90233140
Premature baby 49.44 16.41 48 26524 25029 90576846
Antacid therapy 48.49 16.41 15 26557 739 90601136
Appendicolith 48.35 16.41 15 26557 746 90601129
Drug therapy 47.45 16.41 15 26557 794 90601081
Anticoagulant therapy 47.30 16.41 15 26557 802 90601073
Excessive eye blinking 47.05 16.41 17 26555 1355 90600520
Peripheral swelling 46.68 16.41 32 26540 413074 90188801
International normalised ratio increased 46.25 16.41 63 26509 47253 90554622
Wound 45.51 16.41 16 26556 302964 90298911
Product use issue 45.32 16.41 20 26552 329899 90271976
Influenza A virus test positive 44.78 16.41 13 26559 514 90601361
Hepatic enzyme increased 43.41 16.41 26 26546 360710 90241165
Foetal exposure during pregnancy 43.19 16.41 58 26514 42917 90558958
Psoriatic arthropathy 42.02 16.41 8 26564 228327 90373548
Toxicity to various agents 40.24 16.41 17 26555 287829 90314046
Hepatitis infectious mononucleosis 39.68 16.41 9 26563 129 90601746
Irritable bowel syndrome 38.74 16.41 7 26565 207441 90394434
Accidental overdose 37.76 16.41 44 26528 28229 90573646
Abdominal discomfort 36.62 16.41 52 26520 477276 90124599
Hyperphosphataemia 36.44 16.41 19 26553 3692 90598183
Stevens-Johnson syndrome 36.40 16.41 44 26528 29332 90572543
Fibromyalgia 36.35 16.41 8 26564 206261 90395614
Pneumonia 36.00 16.41 314 26258 637745 89964130
Stomatitis 35.64 16.41 18 26554 274680 90327195
Ill-defined disorder 35.05 16.41 6 26566 184885 90416990
Dysphoria 34.83 16.41 22 26550 6132 90595743
Nasopharyngitis 34.67 16.41 41 26531 407063 90194812
Hypertension 33.96 16.41 51 26521 457481 90144394
Wheezing 32.39 16.41 147 26425 237933 90363942
Completed suicide 31.61 16.41 3 26569 145055 90456820
Discomfort 31.30 16.41 21 26551 274314 90327561
Hypothermia 31.05 16.41 30 26542 15545 90586330
Respiratory distress 30.94 16.41 47 26525 38899 90562976
Colitis ischaemic 30.88 16.41 27 26545 12319 90589556
Thinking abnormal 30.04 16.41 26 26546 11706 90590169
Idiosyncratic drug reaction 29.48 16.41 11 26561 960 90600915
Musculoskeletal pain 29.45 16.41 7 26565 171244 90430631
Haemorrhagic diathesis 29.41 16.41 19 26553 5505 90596370
Loss of consciousness 29.17 16.41 99 26473 140139 90461736
Intermenstrual bleeding 28.95 16.41 23 26549 9200 90592675
Migraine 28.67 16.41 10 26562 190382 90411493
Incorrect dose administered 28.47 16.41 68 26504 78862 90523013
Blood phosphorus increased 28.43 16.41 17 26555 4301 90597574
Hypoxia 27.89 16.41 64 26508 72335 90529540
Dyspnoea 27.68 16.41 386 26186 880569 89721306
Rheumatoid arthritis 27.30 16.41 40 26532 362574 90239301
Primary myelofibrosis 27.22 16.41 6 26566 75 90601800
Injury 27.02 16.41 12 26560 197337 90404538
Arthralgia 27.00 16.41 127 26445 778395 89823480
Delirium febrile 26.89 16.41 5 26567 24 90601851
Appendicitis 26.86 16.41 23 26549 10208 90591667
Abortion spontaneous 26.86 16.41 53 26519 54003 90547872
Glomerulonephritis minimal lesion 26.47 16.41 8 26564 364 90601511
Purpura senile 26.37 16.41 9 26563 606 90601269
Low birth weight baby 26.33 16.41 22 26550 9445 90592430
Atelectasis 26.15 16.41 34 26538 24375 90577500
Skin warm 25.92 16.41 20 26552 7667 90594208
Dyspepsia 25.67 16.41 13 26559 198147 90403728
Blood viscosity abnormal 25.24 16.41 7 26565 234 90601641
Hallucination, auditory 24.99 16.41 27 26545 15948 90585927
Appetite disorder 24.93 16.41 21 26551 9112 90592763
Aortic stenosis 24.74 16.41 18 26554 6318 90595557
Hypersensitivity 24.68 16.41 222 26350 454455 90147420
Bronchopleural fistula 24.53 16.41 7 26565 260 90601615
Iris transillumination defect 24.08 16.41 6 26566 131 90601744
Sinusitis 23.77 16.41 40 26532 343048 90258827
Bursitis 23.40 16.41 5 26567 131649 90470226
Therapeutic product effect incomplete 23.27 16.41 14 26558 193882 90407993
Arthritis infective 23.11 16.41 19 26553 7973 90593902
Tarsal tunnel syndrome 23.02 16.41 8 26564 569 90601306
Screaming 22.72 16.41 14 26558 3736 90598139
Urticaria 22.56 16.41 163 26409 312571 90289304
PaO2/FiO2 ratio decreased 22.31 16.41 4 26568 15 90601860
Agitation 22.28 16.41 56 26516 67042 90534833
Hepatitis fulminant 22.07 16.41 14 26558 3931 90597944
Delirium 21.99 16.41 74 26498 104285 90497590
Pain in extremity 21.81 16.41 64 26508 450465 90151410
Tachypnoea 21.78 16.41 29 26543 21280 90580595
Activated partial thromboplastin time prolonged 21.38 16.41 18 26554 7807 90594068
Inflammation 21.28 16.41 13 26559 178579 90423296
Delusion 20.97 16.41 23 26549 13817 90588058
Obesity 20.95 16.41 3 26569 105504 90496371
Multiple organ dysfunction syndrome 20.60 16.41 55 26517 68281 90533594
Headache 20.57 16.41 361 26211 862385 89739490
Apgar score low 20.51 16.41 9 26563 1194 90600681
Foetal growth restriction 20.48 16.41 19 26553 9361 90592514
Abortion induced 20.21 16.41 21 26551 11867 90590008
Gait inability 19.90 16.41 9 26563 146447 90455428
Lung disorder 19.23 16.41 91 26481 149792 90452083
Malaise 18.89 16.41 98 26474 585888 90015987
Neonatal pneumonia 18.61 16.41 4 26568 44 90601831
Disseminated intravascular coagulation 18.55 16.41 27 26545 21511 90580364
Oliguria 18.48 16.41 19 26553 10605 90591270
Muscular weakness 18.46 16.41 20 26552 206646 90395229
Vestibular disorder 18.33 16.41 9 26563 1540 90600335
Erythema multiforme 17.94 16.41 20 26552 12226 90589649
Hepatic function abnormal 17.92 16.41 41 26531 46247 90555628
Hypercholesterolaemia 17.59 16.41 4 26568 100888 90500987
Blood uric acid increased 17.59 16.41 16 26556 7688 90594187
Arthritis 17.53 16.41 14 26558 167301 90434574
Toxic epidermal necrolysis 17.51 16.41 33 26539 32495 90569380
Photophobia 17.37 16.41 26 26546 21243 90580632
Right atrial dilatation 17.36 16.41 7 26565 752 90601123
Resorption bone increased 17.23 16.41 8 26564 1211 90600664
Infantile apnoea 16.81 16.41 8 26564 1279 90600596
Sleep disorder therapy 16.58 16.41 6 26566 480 90601395
Drug intolerance 16.45 16.41 202 26370 447389 90154486

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abnormal behaviour 1032.49 17.56 423 22353 26028 42572531
No adverse event 637.83 17.56 342 22434 38679 42559880
Appendicolith 337.88 17.56 158 22618 13298 42585261
Off label use 330.30 17.56 909 21867 637426 41961133
Appendicitis 282.33 17.56 161 22615 20452 42578107
Normal newborn 266.27 17.56 57 22719 312 42598247
Blood phosphorus increased 250.84 17.56 126 22650 12399 42586160
Ventricular fibrillation 230.94 17.56 163 22613 29960 42568599
Myasthenia gravis 218.15 17.56 125 22651 16012 42582547
Stress 203.59 17.56 177 22599 44035 42554524
Multiple organ dysfunction syndrome 202.34 17.56 254 22522 96781 42501778
Influenza 200.09 17.56 204 22572 61971 42536588
Cardiogenic shock 200.02 17.56 160 22616 35480 42563079
Hyperphosphataemia 192.73 17.56 107 22669 12897 42585662
Hallucination 174.76 17.56 183 22593 57324 42541235
Analgesic therapy 168.02 17.56 78 22698 6446 42592113
Bacterial infection 158.19 17.56 126 22650 27753 42570806
Sleep disorder therapy 157.83 17.56 76 22700 6818 42591741
Incorrect route of product administration 151.21 17.56 116 22660 24189 42574370
Drug therapy 151.12 17.56 72 22704 6308 42592251
Ascites 150.53 17.56 168 22608 56510 42542049
Blood uric acid increased 147.40 17.56 96 22680 15451 42583108
Neuralgia 143.55 17.56 115 22661 25532 42573027
Delirium 140.02 17.56 156 22620 52363 42546196
Abdominal distension 137.17 17.56 180 22596 71555 42527004
Hypophosphataemia 136.98 17.56 103 22673 20842 42577717
Blood cholesterol increased 120.89 17.56 106 22670 26635 42571924
Vomiting 120.80 17.56 384 22392 289339 42309220
Dry mouth 115.92 17.56 124 22652 39755 42558804
Pathogen resistance 111.72 17.56 72 22704 11378 42587181
Hyponatraemia 110.54 17.56 196 22580 101266 42497293
Iron deficiency 106.55 17.56 69 22707 10992 42587567
Antacid therapy 104.95 17.56 51 22725 4666 42593893
Anticoagulant therapy 97.80 17.56 48 22728 4487 42594072
Activated partial thromboplastin time prolonged 96.92 17.56 75 22701 15828 42582731
Exposure during pregnancy 88.98 17.56 56 22720 8492 42590067
Swelling 84.30 17.56 124 22652 54761 42543798
Ulcer 82.07 17.56 69 22707 16372 42582187
Sleep disorder 80.21 17.56 113 22663 47982 42550577
Sepsis 79.05 17.56 260 22516 199074 42399485
End stage renal disease 77.56 17.56 67 22709 16491 42582068
Diabetes mellitus 73.14 17.56 122 22654 59965 42538594
JC virus infection 68.39 17.56 33 22743 2971 42595588
Intentional product misuse 67.88 17.56 120 22656 61780 42536779
Thrombosis 64.05 17.56 124 22652 68387 42530172
Congenital hiatus hernia 63.14 17.56 40 22736 6134 42592425
Blood calcium increased 62.99 17.56 45 22731 8409 42590150
Bacteroides infection 60.66 17.56 29 22747 2558 42596001
Troponin increased 60.22 17.56 62 22714 19000 42579559
Bronchopulmonary aspergillosis allergic 57.81 17.56 34 22742 4564 42593995
Aortic stenosis 57.14 17.56 43 22733 8702 42589857
Pneumonia influenzal 55.76 17.56 25 22751 1904 42596655
Somnolence 54.02 17.56 182 22594 140923 42457636
Pleuritic pain 53.49 17.56 38 22738 7039 42591520
Blood test abnormal 52.06 17.56 48 22728 12858 42585701
General physical health deterioration 51.78 17.56 188 22588 151058 42447501
Abdominal pain 49.36 17.56 217 22559 190254 42408305
Hyperlipidaemia 49.04 17.56 59 22717 21457 42577102
Fatigue 48.69 17.56 100 22676 435541 42163018
Weight decreased 46.08 17.56 27 22749 207921 42390638
Gout 45.39 17.56 65 22711 27990 42570569
Hypotension 43.68 17.56 44 22732 257587 42340972
Micturition urgency 41.80 17.56 41 22735 11857 42586702
Toxicity to various agents 41.33 17.56 37 22739 229099 42369460
Drug intolerance 40.30 17.56 114 22662 80310 42518249
Dizziness 39.54 17.56 45 22731 249209 42349350
Hallucination, visual 38.96 17.56 52 22724 20968 42577591
Total lung capacity decreased 38.69 17.56 24 22752 3546 42595013
Bronchopulmonary aspergillosis 37.45 17.56 49 22727 19380 42579179
Acute respiratory distress syndrome 36.43 17.56 61 22715 30047 42568512
Constipation 36.18 17.56 177 22599 162114 42436445
Chronic obstructive pulmonary disease 35.14 17.56 93 22683 63021 42535538
Arthralgia 34.82 17.56 35 22741 205203 42393356
Malignant neoplasm progression 34.14 17.56 8 22768 108392 42490167
Urinary tract inflammation 33.37 17.56 10 22766 238 42598321
Condition aggravated 32.85 17.56 245 22531 260509 42338050
Drug hypersensitivity 32.68 17.56 122 22654 99267 42499292
Liver disorder 31.38 17.56 67 22709 39577 42558982
Respiratory symptom 31.30 17.56 34 22742 11072 42587487
Cardiac failure congestive 29.71 17.56 5 22771 85597 42512962
Progressive multifocal leukoencephalopathy 28.54 17.56 33 22743 11503 42587056
Influenza A virus test positive 28.41 17.56 10 22766 401 42598158
Joint injury 28.26 17.56 37 22739 14639 42583920
Decreased appetite 27.33 17.56 38 22738 193099 42405460
Breath sounds abnormal 27.29 17.56 33 22743 12060 42586499
Upper respiratory tract infection 26.43 17.56 65 22711 42108 42556451
Rash morbilliform 26.20 17.56 20 22756 4133 42594426
Lung opacity 26.08 17.56 23 22753 5814 42592745
Seizure 25.78 17.56 130 22646 120431 42478128
Sleep terror 25.14 17.56 17 22759 2909 42595650
Porphyria acute 24.53 17.56 9 22767 407 42598152
Pulmonary embolism 24.20 17.56 127 22649 119485 42479074
Aspiration 22.66 17.56 37 22739 17849 42580710
Conductive deafness 22.63 17.56 9 22767 508 42598051
Hypercholesterolaemia 22.61 17.56 31 22745 12818 42585741
Accidental overdose 22.55 17.56 48 22728 28282 42570277
Myocardial infarction 22.36 17.56 20 22756 123989 42474570
Fall 21.97 17.56 59 22717 234461 42364098
Enterocolitis haemorrhagic 21.90 17.56 11 22765 1080 42597479
Immunosuppressant drug level decreased 21.66 17.56 13 22763 1811 42596748
Dehydration 20.95 17.56 27 22749 141740 42456819
Transaminases increased 20.94 17.56 51 22725 32834 42565725
Death 20.83 17.56 157 22619 471028 42127531
Lymphocyte stimulation test positive 20.78 17.56 9 22767 631 42597928
Crying 20.56 17.56 21 22755 6373 42592186
Cardiovascular disorder 20.21 17.56 30 22746 13335 42585224
Congenital heart valve disorder 20.12 17.56 5 22771 57 42598502
Central vision loss 19.92 17.56 4 22772 15 42598544
Pneumonia 19.84 17.56 326 22450 421823 42176736
Hepatitis cholestatic 19.28 17.56 25 22751 9799 42588760
Nausea 18.85 17.56 307 22469 396492 42202067
Haemoglobin decreased 18.79 17.56 26 22750 132445 42466114
Weight increased 18.77 17.56 18 22758 107965 42490594
Toxic epidermal necrolysis 18.67 17.56 43 22733 26707 42571852
H1N1 influenza 18.40 17.56 10 22766 1154 42597405
Lower respiratory tract infection 18.32 17.56 56 22720 41150 42557409
Delirium febrile 18.23 17.56 4 22772 25 42598534
Infusion related reaction 18.15 17.56 5 22771 60801 42537758
Drug resistance 17.58 17.56 49 22727 34199 42564360

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abnormal behaviour 1465.17 15.13 557 42688 38482 110507572
No adverse event 591.17 15.13 365 42880 73474 110472580
Appendicolith 427.18 15.13 173 43072 14082 110531972
Off label use 378.09 15.13 1361 41884 1498824 109047230
Appendicitis 349.27 15.13 186 43059 28278 110517776
Hallucination 325.33 15.13 289 42956 101143 110444911
Influenza 320.57 15.13 362 42883 168739 110377315
Blood phosphorus increased 308.07 15.13 143 43102 16197 110529857
Chest X-ray abnormal 292.63 15.13 114 43131 8373 110537681
Ear pruritus 287.95 15.13 108 43137 7152 110538902
Pulmonary function test abnormal 283.77 15.13 97 43148 4903 110541151
Hyperphosphataemia 258.92 15.13 127 43118 16254 110529800
Ventricular fibrillation 253.63 15.13 173 43072 41140 110504914
Myasthenia gravis 248.31 15.13 135 43110 21376 110524678
Breath sounds abnormal 245.84 15.13 142 43103 25262 110520792
Pathogen resistance 243.98 15.13 125 43120 17547 110528507
Exposure during pregnancy 238.21 15.13 310 42935 167114 110378940
Analgesic therapy 237.62 15.13 94 43151 7190 110538864
Multiple organ dysfunction syndrome 230.13 15.13 290 42955 151420 110394634
Cardiogenic shock 217.64 15.13 180 43065 57158 110488896
Drug therapy 216.74 15.13 88 43157 7203 110538851
Blood lactic acid increased 215.79 15.13 111 43134 15710 110530344
Drug ineffective for unapproved indication 215.23 15.13 232 43013 102606 110443448
Nasal polyps 198.69 15.13 99 43146 13101 110532953
Sleep disorder therapy 197.78 15.13 83 43162 7388 110538666
Swollen tongue 195.46 15.13 173 43072 60189 110485865
Rhinitis allergic 189.06 15.13 106 43139 17816 110528238
Blood uric acid increased 186.40 15.13 112 43133 21417 110524637
Upper-airway cough syndrome 181.58 15.13 99 43146 15758 110530296
Bacterial infection 175.70 15.13 145 43100 45891 110500163
Swelling face 175.39 15.13 198 43047 92123 110453931
Ascites 162.76 15.13 191 43054 92617 110453437
Full blood count abnormal 162.53 15.13 151 43094 55901 110490153
Antacid therapy 162.36 15.13 66 43179 5418 110540636
Sneezing 159.47 15.13 118 43127 31866 110514188
Platelet count increased 158.59 15.13 109 43136 26225 110519829
Anticoagulant therapy 153.52 15.13 63 43182 5298 110540756
Dysphonia 153.08 15.13 168 43077 75761 110470293
Hypophosphataemia 144.66 15.13 113 43132 33069 110512985
Angioedema 144.08 15.13 185 43060 98315 110447739
Stress 141.90 15.13 190 43055 105158 110440896
Enterocolitis haemorrhagic 137.99 15.13 48 43197 2556 110543498
Lacrimation increased 136.23 15.13 106 43139 30844 110515210
Activated partial thromboplastin time prolonged 130.96 15.13 91 43154 22277 110523777
Eye pruritus 130.87 15.13 106 43139 32669 110513385
Acute respiratory distress syndrome 129.16 15.13 130 43115 53068 110492986
Vasculitis 128.62 15.13 109 43136 35764 110510290
Delirium 127.51 15.13 206 43039 134819 110411235
Neuralgia 126.09 15.13 123 43122 48355 110497699
Vomiting 123.81 15.13 690 42555 909985 109636069
Premature delivery 113.78 15.13 95 43150 30537 110515517
Fatigue 113.08 15.13 189 43056 1215769 109330285
End stage renal disease 111.05 15.13 81 43164 21392 110524662
Iron deficiency 107.78 15.13 75 43170 18401 110527653
Blood potassium decreased 104.34 15.13 117 43128 53997 110492057
Incorrect route of product administration 96.30 15.13 122 43123 63939 110482115
Hyponatraemia 96.28 15.13 242 43003 217411 110328643
Alopecia 94.04 15.13 15 43230 364738 110181316
Aortic stenosis 92.97 15.13 60 43185 12999 110533055
Abdominal distension 91.81 15.13 208 43037 174895 110371159
Synovitis 90.15 15.13 4 43241 274088 110271966
Sepsis 88.18 15.13 305 42940 327041 110219013
Pneumonia influenzal 86.63 15.13 38 43207 3767 110542287
Rhinorrhoea 85.37 15.13 148 43097 102518 110443536
Eosinophilia 84.98 15.13 109 43136 57827 110488227
Infusion related reaction 83.25 15.13 23 43222 381139 110164915
Systemic lupus erythematosus 82.71 15.13 4 43241 254334 110291720
Therapeutic product effect decreased 82.25 15.13 3 43242 244313 110301741
Weight increased 79.99 15.13 32 43213 419612 110126442
Seizure 79.72 15.13 228 43017 220957 110325097
Diabetes mellitus 78.41 15.13 140 43105 99241 110446813
Congenital hiatus hernia 77.02 15.13 41 43204 6218 110539836
Thrombosis 76.82 15.13 146 43099 108516 110437538
Gout 75.57 15.13 82 43163 36484 110509570
Blood calcium increased 75.53 15.13 60 43185 17980 110528074
Toxicity to various agents 74.63 15.13 48 43197 480507 110065547
Mobility decreased 73.32 15.13 5 43240 237417 110308637
Hyperlipidaemia 71.67 15.13 79 43166 35769 110510285
Influenza A virus test positive 68.96 15.13 23 43222 1077 110544977
H1N1 influenza 68.26 15.13 30 43215 2988 110543066
Contraindicated product administered 66.77 15.13 9 43236 248258 110297796
Joint swelling 66.38 15.13 46 43199 442799 110103255
Bacteroides infection 65.97 15.13 29 43216 2890 110543164
Peripheral swelling 64.60 15.13 39 43206 403995 110142059
Respiratory syncytial virus infection 64.58 15.13 50 43195 14434 110531620
Pain 63.99 15.13 178 43067 954777 109591277
Troponin increased 63.70 15.13 68 43177 29698 110516356
Respiratory failure 63.57 15.13 207 43038 215125 110330929
Pericarditis 61.22 15.13 7 43238 219107 110326947
Impaired healing 61.16 15.13 4 43241 196713 110349341
JC virus infection 60.48 15.13 33 43212 5257 110540797
Treatment failure 60.01 15.13 17 43228 277217 110268837
Pleuritic pain 59.82 15.13 50 43195 16090 110529964
Blood test abnormal 58.94 15.13 64 43181 28490 110517564
Intentional product misuse 57.92 15.13 147 43098 132757 110413297
Arthralgia 57.81 15.13 138 43107 779494 109766560
Nasal congestion 57.44 15.13 122 43123 98160 110447894
Product use issue 57.39 15.13 25 43220 311670 110234384
Accidental overdose 57.17 15.13 85 43160 51749 110494305
Drug intolerance 56.28 15.13 310 42935 406202 110139852
Psoriatic arthropathy 55.69 15.13 6 43239 196755 110349299
Ulcer 55.34 15.13 76 43169 43040 110503014
Pneumonia 55.23 15.13 554 42691 876160 109669894
Influenza virus test positive 54.33 15.13 16 43229 495 110545559
Bronchopulmonary aspergillosis allergic 53.39 15.13 36 43209 8390 110537664
Chronic obstructive pulmonary disease 52.07 15.13 125 43120 109033 110437021
Abdominal pain 51.42 15.13 360 42885 512629 110033425
Nasopharyngitis 50.32 15.13 48 43197 394313 110151741
Hepatic enzyme increased 49.86 15.13 32 43213 320860 110225194
Fibromyalgia 48.91 15.13 5 43240 170904 110375150
Musculoskeletal pain 48.35 15.13 7 43238 183016 110363038
Wound 47.81 15.13 16 43229 234421 110311633
Hypothermia 47.52 15.13 55 43190 26247 110519807
Completed suicide 46.95 15.13 18 43227 242363 110303691
Constipation 45.65 15.13 267 42978 357519 110188535
Weight decreased 44.94 15.13 71 43174 467986 110078068
Stomatitis 44.71 15.13 25 43220 270217 110275837
Asthma 44.57 15.13 205 43040 250086 110295968
Total lung capacity decreased 44.13 15.13 30 43215 7084 110538970
Irritable bowel syndrome 44.03 15.13 6 43239 164209 110381845
Glossodynia 43.81 15.13 16 43229 221988 110324066
Hallucination, visual 43.75 15.13 65 43180 39540 110506514
Abdominal discomfort 42.49 15.13 55 43190 393803 110152251
Migraine 42.15 15.13 8 43237 171644 110374410
Micturition urgency 41.10 15.13 44 43201 19276 110526778
International normalised ratio increased 40.99 15.13 99 43146 86673 110459381
Excessive eye blinking 40.40 15.13 18 43227 1852 110544202
Bronchopulmonary aspergillosis 40.39 15.13 54 43191 29809 110516245
Intentional overdose 40.29 15.13 3 43242 132498 110413556
Inflammation 39.73 15.13 13 43232 193225 110352829
Malaise 39.37 15.13 133 43112 671686 109874368
Hypotension 39.35 15.13 92 43153 523757 110022297
Muscle spasms 38.93 15.13 31 43214 278126 110267928
Somnolence 38.59 15.13 223 43022 297226 110248828
Pulmonary embolism 37.68 15.13 175 43070 214299 110331755
Dizziness 37.09 15.13 144 43101 698049 109848005
Bursitis 36.66 15.13 4 43241 129914 110416140
Therapeutic product effect incomplete 36.60 15.13 21 43224 223784 110322270
Pregnancy 36.55 15.13 69 43176 50998 110495056
Lymphocyte stimulation test positive 35.74 15.13 14 43231 1042 110545012
Stevens-Johnson syndrome 35.61 15.13 65 43180 46836 110499218
Pain in extremity 35.43 15.13 87 43158 487031 110059023
Toxic epidermal necrolysis 34.98 15.13 72 43173 56655 110489399
Malignant neoplasm progression 33.74 15.13 13 43232 174554 110371500
Colitis ischaemic 33.56 15.13 38 43207 17712 110528342
Muscular weakness 33.15 15.13 29 43216 248439 110297615
Lung opacity 33.01 15.13 31 43214 11621 110534433
Injury 32.96 15.13 14 43231 177251 110368803
Chest discomfort 32.89 15.13 145 43100 173703 110372351
Hepatitis infectious mononucleosis 32.70 15.13 9 43236 217 110545837
Dyspepsia 32.56 15.13 17 43228 190948 110355106
Urinary tract inflammation 31.79 15.13 10 43235 388 110545666
Respiratory symptom 31.73 15.13 34 43211 14911 110531143
Ill-defined disorder 31.46 15.13 11 43234 156842 110389212
Thinking abnormal 31.36 15.13 34 43211 15106 110530948
Fall 31.06 15.13 126 43119 603356 109942698
Loss of consciousness 30.75 15.13 155 43090 196151 110349903
Obesity 30.72 15.13 4 43241 113347 110432707
Drug resistance 30.67 15.13 68 43177 56306 110489748
Hepatitis fulminant 30.65 15.13 26 43219 8534 110537520
Maternal exposure during pregnancy 30.43 15.13 187 43058 254696 110291358
Arthritis 29.96 15.13 14 43231 167572 110378482
Discomfort 29.95 15.13 24 43221 214683 110331371
Conductive deafness 29.95 15.13 9 43236 299 110545755
C-reactive protein abnormal 29.88 15.13 7 43238 129688 110416366
Benign prostatic hyperplasia 29.43 15.13 36 43209 18198 110527856
Hallucination, auditory 28.69 15.13 43 43202 26354 110519700
Myocardial infarction 28.68 15.13 20 43225 192063 110353991
Infection 28.49 15.13 62 43183 362138 110183916
Dysphoria 28.24 15.13 22 43223 6406 110539648
Rheumatoid arthritis 28.21 15.13 46 43199 299567 110246487
Sleep disorder 27.78 15.13 152 43093 198492 110347562
Delusion 27.70 15.13 40 43205 23715 110522339
Aspergillus infection 26.81 15.13 41 43204 25575 110520479
Delirium febrile 26.28 15.13 6 43239 65 110545989
Hypoxia 26.01 15.13 110 43135 129405 110416649
Cardiac failure congestive 24.92 15.13 14 43231 150986 110395068
Sinusitis 23.98 15.13 50 43195 296638 110249416
Gait inability 23.45 15.13 12 43233 136364 110409690
Injection site pain 23.45 15.13 21 43224 177901 110368153
Haemorrhagic diathesis 23.26 15.13 21 43224 7487 110538567
Incorrect dose administered 23.16 15.13 91 43154 103550 110442504
Adverse event 22.93 15.13 7 43238 108802 110437252
Blood viscosity abnormal 22.75 15.13 7 43238 252 110545802
Agitation 22.68 15.13 96 43149 112955 110433099
Intermenstrual bleeding 22.68 15.13 20 43225 6914 110539140
Mucosal inflammation 22.52 15.13 5 43240 96136 110449918
Cough 22.23 15.13 277 42968 461364 110084690
Screaming 22.09 15.13 17 43228 4864 110541190
Fluid retention 21.90 15.13 5 43240 94302 110451752
Abdominal pain upper 21.89 15.13 67 43178 349044 110197010
Aspiration 21.53 15.13 41 43204 30492 110515562
Transaminases increased 21.51 15.13 64 43181 63326 110482728
Depressed level of consciousness 21.49 15.13 94 43151 112184 110433870
Product use in unapproved indication 21.35 15.13 268 42977 447109 110098945
Hypokalaemia 21.22 15.13 24 43221 182424 110363630
Restlessness 21.22 15.13 59 43186 56200 110489854
Tarsal tunnel syndrome 21.16 15.13 8 43237 541 110545513
Nosocomial infection 21.07 15.13 14 43231 3185 110542869
Blood cholesterol increased 21.06 15.13 134 43111 184651 110361403
Overdose 21.03 15.13 160 43085 233634 110312420
Encephalitis influenzal 20.54 15.13 3 43242 0 110546054
Depression 20.54 15.13 60 43185 317275 110228779
Hepatic function abnormal 20.44 15.13 79 43166 89216 110456838
Immunosuppressant drug level decreased 20.39 15.13 13 43232 2758 110543296
Dry mouth 20.37 15.13 141 43104 199807 110346247
Rash morbilliform 20.34 15.13 20 43225 7931 110538123
Purpura senile 20.28 15.13 8 43237 607 110545447
Iris transillumination defect 19.92 15.13 6 43239 201 110545853
Primary myelofibrosis 19.75 15.13 6 43239 207 110545847
Hepatitis cholestatic 19.64 15.13 29 43216 17537 110528517
Erythema multiforme 19.63 15.13 32 43213 21065 110524989
Psychiatric symptom 19.63 15.13 21 43224 9192 110536862
Progressive multifocal leukoencephalopathy 19.47 15.13 35 43210 24921 110521133
Blood pressure fluctuation 19.44 15.13 3 43242 74821 110471233
Haemoglobin decreased 19.20 15.13 43 43202 248684 110297370
Road traffic accident 19.15 15.13 9 43236 107389 110438665
Cataract 18.89 15.13 4 43241 79481 110466573
Idiosyncratic drug reaction 18.73 15.13 10 43235 1526 110544528
Adverse drug reaction 18.58 15.13 9 43236 105550 110440504
Atelectasis 18.54 15.13 43 43202 36669 110509385
Frequent bowel movements 18.23 15.13 3 43242 71387 110474667
Urinary tract infection 18.13 15.13 66 43179 326216 110219838
Skin warm 17.96 15.13 20 43225 9150 110536904
Cardiovascular disorder 17.86 15.13 32 43213 22728 110523326
Asthenia 17.74 15.13 178 43067 688821 109857233
Sciatica 17.65 15.13 7 43238 92392 110453662
Infective pulmonary exacerbation of cystic fibrosis 17.41 15.13 25 43220 14746 110531308
Joint injury 17.16 15.13 44 43201 39950 110506104
Upper respiratory tract inflammation 17.15 15.13 14 43231 4357 110541697
Hypertension 17.07 15.13 123 43122 509961 110036093
Lymphopenia 17.04 15.13 44 43201 40126 110505928
Appetite disorder 16.93 15.13 20 43225 9749 110536305
Nightmare 16.93 15.13 43 43202 38820 110507234
Respiratory distress 16.64 15.13 62 43183 68812 110477242
Lung disorder 16.62 15.13 124 43121 179923 110366131
Injection site erythema 16.62 15.13 8 43237 94168 110451886
Balance disorder 16.28 15.13 13 43232 116547 110429507
Autoimmune disorder 16.18 15.13 3 43242 65480 110480574
Osteoporosis 16.01 15.13 7 43238 87145 110458909
Cardiac disorder 15.91 15.13 5 43240 76275 110469779
Glomerulonephritis minimal lesion 15.88 15.13 8 43237 1083 110544971
Febrile convulsion 15.75 15.13 8 43237 1102 110544952
Central vision loss 15.75 15.13 4 43241 70 110545984
Placental necrosis 15.72 15.13 3 43242 12 110546042
Influenza B virus test positive 15.70 15.13 6 43239 418 110545636
Drug ineffective 15.64 15.13 735 42510 1519805 109026249
Oedema 15.64 15.13 37 43208 209939 110336115
Paraesthesia 15.32 15.13 56 43189 276465 110269589
Aspartate aminotransferase increased 15.25 15.13 111 43134 159825 110386229
Memory impairment 15.24 15.13 34 43211 196910 110349144
Blood pressure increased 15.20 15.13 51 43194 258322 110287732

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AH02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Neuraminidase inhibitors
FDA MoA N0000175436 Neuraminidase Inhibitors
FDA EPC N0000175524 Neuraminidase Inhibitor
CHEBI has role CHEBI:74518 anti-obesity agent
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:52425 EC 3.2.1.18 (<i>exo</i>-ฮฑ-sialidase) inhibitor
CHEBI has role CHEBI:78298 environmental contaminant
CHEBI has role CHEBI:231911 renoprotective agent
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
CHEBI has role CHEBI:83399 marine xenobiotic metabolite

Related Drugs by ATC class:

J05AH Neuraminidase inhibitors 3 drugs
laninamivir octanoate hydrateperamivirzanamivir

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Influenza indication 6142004 DOID:8469
Coronavirus infection off-label use 186747009
Delirium contraindication 2776000
Suicidal thoughts contraindication 6471006
Acute nephropathy contraindication 58574008
Impaired cognition contraindication 386806002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.54 acidic
pKa2 7.67 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Neuraminidase Enzyme INHIBITOR Ki 8.96 CHEMBL CHEMBL
Neuraminidase Enzyme INHIBITOR IC50 8.15 CHEMBL CHEMBL
Neuraminidase Enzyme IC50 10.22 CHEMBL
Sialidase Enzyme IC50 9 CHEMBL
Neuraminidase Enzyme IC50 8.81 CHEMBL
Neuraminidase Enzyme Ki 10 CHEMBL
Neuraminidase Enzyme Ki 8.10 CHEMBL
Neuraminidase Enzyme Ki 8.31 CHEMBL
Neuraminidase Enzyme Ki 8.96 CHEMBL
Neuraminidase Enzyme IC50 8.54 CHEMBL
Neuraminidase Enzyme IC50 6.32 CHEMBL
Neuraminidase Enzyme IC50 6.10 CHEMBL
Neuraminidase Enzyme IC50 8.86 CHEMBL
Neuraminidase Enzyme IC50 8.05 CHEMBL
Neuraminidase Enzyme IC50 9.96 CHEMBL
Neuraminidase Enzyme IC50 7.82 CHEMBL
Neuraminidase Enzyme IC50 9.83 WOMBAT-PK
Neuraminidase Enzyme IC50 6.24 CHEMBL
Neuraminidase Enzyme IC50 8.10 WOMBAT-PK

External reference:

IDSource
4021189 VUID
N0000175097 NUI
D00900 KEGG_DRUG
204255-11-8 SECONDARY_CAS_RN
4021189 VANDF
4021190 VANDF
C0874161 UMLSCUI
CHEBI:7798 CHEBI
G39 PDB_CHEM_ID
CHEMBL1229 ChEMBL_ID
CHEMBL1200340 ChEMBL_ID
DB00198 DRUGBANK_ID
D053139 MESH_DESCRIPTOR_UI
65028 PUBCHEM_CID
11427 IUPHAR_LIGAND_ID
7793 INN_ID
20O93L6F9H UNII
DB02600 DRUGBANK_ID
1546279 RXNORM
247129 MMSL
31447 MMSL
8475 MMSL
d04462 MMSL
007918 NDDF
007919 NDDF
116113006 SNOMEDCT_US
386142008 SNOMEDCT_US
412261005 SNOMEDCT_US
C2713885 UMLSCUI
CHEMBL674 ChEMBL_ID
187227-45-8 SECONDARY_CAS_RN
449381 PUBCHEM_CID
C535162 MESH_SUPPLEMENTAL_RECORD_UI
K6106LV5Q8 UNII
CHEBI:73139 CHEBI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 0004-0800 CAPSULE 75 mg ORAL NDA 28 sections
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 0004-0801 CAPSULE 45 mg ORAL NDA 28 sections
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 0004-0802 CAPSULE 30 mg ORAL NDA 28 sections
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 0004-0822 POWDER, FOR SUSPENSION 6 mg ORAL NDA 28 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0093-8180 POWDER, FOR SUSPENSION 6 mg ORAL ANDA 27 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0527-4591 CAPSULE 30 mg ORAL ANDA 28 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0527-4592 CAPSULE 45 mg ORAL ANDA 28 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0527-4593 CAPSULE 75 mg ORAL ANDA 28 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0527-5137 SUSPENSION 6 mg ORAL ANDA 28 sections
Oseltamivir phosphate Human Prescription Drug Label 1 27241-139 FOR SUSPENSION 6 mg ORAL ANDA 25 sections
Oseltamivir phosphate HUMAN PRESCRIPTION DRUG LABEL 1 31722-108 POWDER, FOR SUSPENSION 6 mg ORAL ANDA 29 sections
Oseltamivir Phosphate Human Prescription Drug Label 1 31722-630 CAPSULE 30 mg ORAL ANDA 25 sections
Oseltamivir Phosphate Human Prescription Drug Label 1 31722-631 CAPSULE 45 mg ORAL ANDA 25 sections
Oseltamivir Phosphate Human Prescription Drug Label 1 31722-632 CAPSULE 75 mg ORAL ANDA 25 sections
oseltamavir phosphate Human Prescription Drug Label 1 33342-256 CAPSULE 30 mg ORAL ANDA 25 sections
oseltamavir phosphate Human Prescription Drug Label 1 33342-256 CAPSULE 30 mg ORAL ANDA 25 sections
oseltamavir phosphate Human Prescription Drug Label 1 33342-257 CAPSULE 45 mg ORAL ANDA 25 sections
oseltamavir phosphate Human Prescription Drug Label 1 33342-257 CAPSULE 45 mg ORAL ANDA 25 sections
oseltamavir phosphate Human Prescription Drug Label 1 33342-258 CAPSULE 75 mg ORAL ANDA 25 sections
oseltamavir phosphate Human Prescription Drug Label 1 33342-258 CAPSULE 75 mg ORAL ANDA 25 sections
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 42254-092 POWDER, FOR SUSPENSION 6 mg ORAL NDA 30 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42291-567 FOR SUSPENSION 6 mg ORAL ANDA 28 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42291-664 CAPSULE 75 mg ORAL ANDA 27 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42291-666 CAPSULE 30 mg ORAL ANDA 27 sections
Oseltamivir Human Prescription Drug Label 1 42385-985 CAPSULE 30 mg ORAL ANDA 24 sections
Oseltamivir Human Prescription Drug Label 1 42385-986 CAPSULE 45 mg ORAL ANDA 24 sections
Oseltamivir Human Prescription Drug Label 1 42385-987 CAPSULE 75 mg ORAL ANDA 24 sections
Oseltamivir phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42677-320 CAPSULE 30 mg ORAL ANDA 19 sections
Oseltamivir phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42677-321 CAPSULE 45 mg ORAL ANDA 19 sections
Oseltamivir phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42677-322 CAPSULE 75 mg ORAL ANDA 19 sections